The updated WHO classification, introduced in 2021, redefined GBM criteria, indicating that patients diagnosed before this change could include those with IDH-mutated tumors, associated with a better prognosis (Kumagai et al., 2023). The gene discussed is IDH1; the disease is glioblastoma.